April 2019

MSD Animal Health Brexit statement

MSD Animal Health is a market leader in the provision of veterinary pharmaceuticals, vaccines and health management solutions in the UK. Continuity of supply after the UK leaves the EU is our priority and we have taken the necessary steps to ensure continued access to veterinary medicines in the UK and EU.

As part of our commitment to acting responsibly and in the best interests of customers, MSD has prepared for all Brexit scenarios, including that of ‘no deal’. MSD’s cross-functional global Brexit project team is dedicated to managing the necessary workload needed to fulfil the requirements and criteria laid out by UK and EU regulators. We have put in place measures to safeguard availability of products, which included reviewing the amount of stock we hold and reconfiguring our commercial distribution routes to avoid as best as possible any delays and disruptions at UK ports and borders. In addition, we are also liaising closely with our wholesalers and corporate partners to plan stock levels and timely supply to our customers.

Throughout the planning process we have followed and applied all recommendations contained within the preparedness notices published by the UK government and the European Commission.

We are confident that our contingency plans across our business have been implemented effectively and will help to ensure that MSD’s supply will not be negatively impacted as a consequence of Brexit.